ADMESeq™ Panel

Raindance Technologies and Ambry Genetics have developed a comprehensive targeted sequencing panel to screen genes involved with drug absorption, distribution, metabolism, and excretion (ADME) research. The RainDance ADMESeq™ Research Screening Panel enables researchers to simultaneously interrogate the coding regions of 242 known pharmacogenetic genes, in a single assay. Researchers can now cost-effectively apply next-generation sequencing (NGS) technology more routinely to detect known and novel mutations leading to adverse drug reactions and events.

In recent years, the biotechnology and pharmaceutical industries have been genotyping ADME genes earlier in the drug development pipeline, to help reduce the significant costs associated with failed drug trials and hospitalizations due to adverse events. However, current genotyping tools interrogate only a small number of known biomarkers and lack the genomic coverage to detect important variants across a wide range of genes implicated with ADME.

Comprehensive Content

The new ADMESeq Research Screening Panel provides scientists with the capacity to perform sequence analysis of entire coding regions of 242 key drug metabolism-linked genes, including 44 membrane transporters, 42 VIP genes from the PharmGKB (Pharmacogenomics Knowledge Base), and 86 FDA-identified pharmacogenomics biomarker genes.

The RainDance ADMESeq™ Research Screening Panel Advantages

• Sequence 242 ADME genes at the same time
• Detect genetically rare variants, not seen with genotyping
• Optimize sequencer efficiency and increase sample throughput
• Apply next-generation sequencing technology more routinely
• Accelerate time to results and simplify workflow

*The RainDance ADMESeq™ Screening Panel is for Research Use Only. Not for use in diagnostic procedures.